Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature

International Journal of Dermatology

Volumn 50, Issue 12, 2011, Pages 1555-1559

  Brewer, Jerry D ^a   Hoverson Schott, Alyssa R ^a   Roenigk, Randall K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; ETRETINATE; FLUOROURACIL; METHOTREXATE; PREDNISONE; PSORALEN; TRIAMCINOLONE; ULOBETASOL PROPIONATE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CASE REPORT; CHEMOSURGERY; CRYOTHERAPY; DERMATOHELIOSIS; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; KERATOACANTHOMA; MALE; PHOTOTHERAPY; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; ULTRAVIOLET B RADIATION;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RISK; SKIN NEOPLASMS;

EID: 81855194685     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05024.x     Document Type: Article

References (18)

1. Feldmann M, Charles P, Taylor P, Maini RN. Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol 1998; 20: 211-228.
2. Becher B, Blain M, Giacomini PS, Antel JP. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J Immunol 1999; 162: 684-688.
3. Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2004; 3: 391-403.
4. Baecklund E, Askling J, Rosenquist R, et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16: 254-261.
5. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-3158.
6. Burge D. Etanercept and squamous cell carcinoma [letter]. J Am Acad Dermatol 2003; 49: 358-359.
7. Comte C, Guilhou JJ, Guillot B, Dereure O. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis [letter]. Dermatology 2008; 217: 284-285.
8. Fryrear RS II, Wiggins AK, Sangueza O, Yosipovitch G. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy [letter]. J Am Acad Dermatol 2004; 51: 1026.
9. Ly L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis [letter]. Br J Dermatol 2007; 157: 1076-1078.
10. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001; 45: 953-956.
11. Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008; 47: 514-518.
12. Gudbrandsdottir S, Larsen R, Sorensen LK, et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004; 22: 118-124.
13. Qin Z, Van Tits LJ, Buurman WA, Blankenstein T. Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice. Blood 1995; 85: 2779-2785.
14. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006; 65: 1578-1584.
15. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-831.
16. Starcher B. Role for tumour necrosis factor-alpha receptors in ultraviolet-induced skin tumours. Br J Dermatol 2000; 142: 1140-1147.
17. Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5years. Arch Dermatol 2005; 141: 861-864.
18. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.